R&D Systems™ Human IFN-gamma Recombinant Protein

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

Supplier:  R&D Systems™ 285IF100/CF

Catalog No. 285IF100CF

Description

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 for this effect is 0.15-0.75 ng/mL.

Specifications

• Formulation: Lyophilized from a 0.2μm filtered solution in Sodium Succinate, Mannitol and Tween™ 80.
• Molecular Weight (g/mol): 16.9 kDa
• Quantity: 100μg
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Recombinant: Recombinant

• Gene ID (Entrez): 3458
• Name: IFN-gamma
• Source: E. coli-derived human IFN-gamma protein Gln24-Gln166 with an N-terminal Met
• Conjugate: Unconjugated
• Purity or Quality Grade: 97%, by SDS-PAGE under reducing conditions and visualized by silver stain.